BioTuesdays

Category - Markets

Fortress Biotech
Markets

Roth starts Fortress Biotech at buy; PT $4

Roth Capital Partners launched coverage of Fortress Biotech (NASDAQ:FBIO), which acquires and develops biopharmaceutical assets, with a “buy” rating and price target of $4. The stock closed at $1.55 on July 1.

July 1, 2019
Merus Logo
Markets

Roth starts Merus at buy; PT $20

Roth Capital Partners launched coverage of Netherlands-based Merus NV (NASDAQ:MRUS) with a “buy” rating and $20 price target. The stock closed at $14.12 on June 27.

June 28, 2019
Atossa Genetics
Markets

Maxim cuts Atossa Genetics to hold and removes its PT

Maxim Group downgraded Atossa Genetics (NASDAQ:ATOS) to “hold” from “buy” and removed its previous price target of $9 after the company reported results from its Phase 2 study evaluating topical endoxifen in patients...

June 27, 2019
Zenabis Logo
Markets

GMP starts Zenabis at buy; PT $3.25

GMP Securities initiated coverage of Zenabis Global (TSX:ZENA) with a “buy” rating and price target of $3.25. The stock was quoted at $1.29 in afternoon trading on June 27.

June 27, 2019
Markets

HCW starts 2 omega-3 companies at buy

H.C. Wainwright launched coverage of Acasti Pharma (NASDAQ:ACST) and Matinas BioPharma (NYSE American:MTNB) with “buy” ratings and price targets of $6 and $4, respectively.

June 26, 2019
ConforMIS
Markets

BTIG ups Conformis PT to $4.50 from $3

BTIG raised its price target for Conformis (NASDAQ:CFMS) to $4.50 from $3 after the company arranged $33-million in debt and equity financing from Innovatus Capital Partners and East West Bank. The stock closed at $3.84...

June 26, 2019
Markets

SVB Leerink cuts Aduro Biotech PT to $5 from $8

SVB Leerink reduced its price target for Aduro Biotech (NASDAQ:ADRO) to $5 from $8 based on recent ADU-S100 (MIW815) Phase1b dose escalation data presentation at ASCO and re-evaluation of development assumptions in the...

June 26, 2019